MGTA - マジェンタ・セラピュ―ティクス (Magenta Therapeutics Inc.) マジェンタ・セラピュ―ティクス

 MGTAのチャート


 MGTAの企業情報

symbol MGTA
会社名 Magenta Therapeutics Inc (マジェンタ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Magenta Therapeutics Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach which aims to reboot the blood and immune systems. The Company’s products include MGTA-145 MGTA-456 E478 and G100. The Company also developing a pipeline of small molecules; biologics including antibody drug conjugates; and a cell therapy which transplant options for many more patients with autoimmune diseases blood cancers and genetic diseases. The Company’s C100 program targets HSCs immune cells and disease-causing cells the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.   マジェンタ・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、自己免疫疾患、血液のがん、希少遺伝病を治療する骨髄移植においてニ―ズの満たされていない分野における治療法の開発に従事する。同社は多発性硬化症、強皮症、急性骨髄性白血病、骨髄異形成症候群、遺伝性代謝疾患の治療に取り組む。本社所在地はマサチュ―セッツ州ケンブリッジ。   Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
本社所在地 50 Hampshire Street Cambridge MA 02139 USA
代表者氏名 Michael W. Bonney マイケル・W・ボニー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 857-201-2700
設立年月日 42156
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.magentatx.com
nasdaq_url https://www.nasdaq.com/symbol/mgta
adr_tso
EBITDA EBITDA(百万ドル) ー
終値(lastsale) 10.5
時価総額(marketcap) 345919717.5
時価総額 時価総額(百万ドル) 331.75350
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) 158.32450
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Magenta Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders totaled to $24.9M.

 MGTAのテクニカル分析


 MGTAのニュース

   Magenta Therapeutics Inc. (MGTA) did well last session?  2022/09/05 14:24:00 US Post News
The share price of Magenta Therapeutics Inc. (NASDAQ:MGTA) fell to $1.73 per share on Friday from $1.75. While Magenta Therapeutics Inc. has underperformed by -1.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MGTA fell by -73.83%, with highs and lows ranging from $8.49 to $0.92, […]
   Magenta Therapeutics Inc. (NASDAQ: MGTA) Is Up 48.89% From Its 52-Week Low; YTD, It Is Down -59.37% – What To Do Now  2022/08/27 17:00:00 Marketing Sentinel
During the last session, Magenta Therapeutics Inc. (NASDAQ:MGTA)’s traded shares were 0.42 million, with the beta value of the company hitting 2.14. At the end of the trading day, the stock’s price was $1.80, reflecting an intraday loss of -3.74% or -$0.07. The 52-week high for the MGTA share is $8.49, that puts it down … Magenta Therapeutics Inc. (NASDAQ: MGTA) Is Up 48.89% From Its 52-Week Low; YTD, It Is Down -59.37% – What To Do Now Read More »
   Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate  2022/08/25 14:10:26 Seeking Alpha
Goldman Sachs has downgraded Magenta Therapeutics (MGTA) from buy to neutral due to a lack of proof-of-concept generating events for one of its lead programs, MGTA-117.
   UPDATE: Goldman Sachs Downgrades Magenta Therapeutics to Neutral  2022/08/24 20:25:04 Investing.com
https://www.investing.com/news/pro/update-goldman-sachs-downgrades-magenta-therapeutics-to-neutral-432SI-2879458
   Magenta Therapeutics Inc. (NASDAQ: MGTA): Is It Stable And Growing?  2022/08/06 15:30:00 Stocks Register
Magenta Therapeutics Inc. (NASDAQ:MGTA) shares, rose in value on Friday, 08/05/22, with the stock price up by 10.32% to the previous day’s close as strong demand from buyers drove the stock to $1.87. Actively observing the price movement in the last trading, the stock closed the session at $1.70, falling within a range of $1.65 … Magenta Therapeutics Inc. (NASDAQ: MGTA): Is It Stable And Growing? Read More »
   Magenta Therapeutics Inc. (NASDAQ: MGTA): Is It Stable And Growing?  2022/08/06 15:30:00 Stocks Register
Magenta Therapeutics Inc. (NASDAQ:MGTA) shares, rose in value on Friday, 08/05/22, with the stock price up by 10.32% to the previous day’s close as strong demand from buyers drove the stock to $1.87. Actively observing the price movement in the last trading, the stock closed the session at $1.70, falling within a range of $1.65 … Magenta Therapeutics Inc. (NASDAQ: MGTA): Is It Stable And Growing? Read More »
   Magenta Therapeutics: Q2 Earnings Insights  2022/08/04 13:42:53 Benzinga
Magenta Therapeutics (NASDAQ: MGTA ) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Magenta Therapeutics beat estimated earnings by 12.12%, reporting an EPS of … Full story available on Benzinga.com
   Magenta Therapeutics GAAP EPS of -$0.29 beats by $0.06  2022/08/04 13:06:46 Seeking Alpha
Magenta Therapeutics press release (MGTA): Q2 GAAP EPS of -$0.29 beats by $0.06.Cash, cash equivalents and marketable securities as of June 30, 2022, were $139.4 million
   Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference  2022/08/02 12:00:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will participate in a Gene Modulation Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference, to be held virtually, on Tuesday, August 9 th , 2022 at 9:45 a.m. ET.
   Tesla, Twitter And 76 Biggest Movers From Friday  2022/07/11 11:30:29 Benzinga
Gainers Seritage Growth Properties (NYSE: SRG ) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale. Aditxt, Inc. (NASDAQ: ADTX ) shares climbed 50% to close at $0.24 on Friday after the company''s Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100. Waitr Holdings Inc. (NASDAQ: WTRH ) gained 48.5% to settle at $0.35 after the company announced a new partnership with Burq to allow deliveries from several new retail industries. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) surged 44.4% to close at $8.20. MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD ) jumped 42.1% to close at $4.25 after gaining 9% on Thursday. Kura Sushi USA, Inc. (NASDAQ: KRUS ) climbed 33.6% to close at $72.29 after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance above analyst estimates.
   Magenta Therapeutics Inc Shares Approach 52-Week Low - Market Mover  2022/01/15 07:47:26 Kwhen Finance
Magenta Therapeutics Inc (MGTA) shares closed today at 1.8% above its 52 week low of $4.40, giving the company a market cap of $273M. The stock is currently up 5.2% year-to-date, down 45.9% over the past 12 months, and down 67.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 70.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.0% lower than its 5-day moving average, 6.7% lower than its 20-day moving average, and 28.4% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -248.1% The company's stock price performance over the past 12 months lags the peer average by 49.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Futures Steady After Fed-Inspired Rout As Tech, Bitcoin Slide Continues  2022/01/06 13:04:22 Zero Hedge
Futures Steady After Fed-Inspired Rout As Tech, Bitcoin Slide Continues US equity futures were little changed after earlier swings as traders digested hawkish Fed minutes that sparked a global stock rout on Wednesday. As discussed yesterday, minutes from the Feds December meeting showed a growing preference for a faster path of rate hikes and a shrinking of the banks balance sheet (one which would lead to yet another market crash and even more stimulus). However, while rising rates is terrible news for tech and high duration names, it''s good news for the value sector, and investors bet while the Fed''s faster-than-expected policy tightening (which will lead to faster than expected easing) may crimp highly valued technology stocks it will offer opportunities in other equity sectors, and sure enough with Nasdaq futures bombing again, energy names like Exxon are at 2 year highs. Treasury yields extended a spike, with the 10Y rising to 1.75%, the dollar was unchanged and bitcoin''s plunge continued even though the selling in stocks has subsided.
   Magenta rises 6% on Goldman Sachs upgrade with $8 target price (NASDAQ:MGTA)  2022/01/06 11:11:19 Seeking Alpha
Goldman Sachs analyst Madhu Kumar upgraded Magenta Therapeutics (MGTA) to Buy from Neutral with a price target ((PT)) of $8, up from $7. Shares up 6% premarket at $4.73
   Magenta Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2021/12/28 04:56:14 Kwhen Finance
Magenta Therapeutics Inc (MGTA) shares closed today at 0.6% above its 52 week low of $4.62, giving the company a market cap of $299M. The stock is currently down 34.9% year-to-date, down 33.8% over the past 12 months, and down 64.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 14.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 21.9% The company's stock price performance over the past 12 months lags the peer average by 11.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors  2021/12/16 12:30:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics to its Board of Directors. Dr. Humphrey is an accomplished clinical researcher and drug developer who has shepherded numerous drugs through all phases of development from pre-IND to post-lau

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マジェンタ・セラピュ―ティクス MGTA Magenta Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)